Singapore markets close in 6 hours 13 minutes

Emergent BioSolutions Inc. (EBS)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
62.37-2.02 (-3.14%)
At close: 4:00PM EDT
62.75 +0.38 (0.61%)
After hours: 06:33PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close64.39
Open64.39
Bid60.70 x 1200
Ask63.95 x 800
Day's range62.16 - 64.39
52-week range55.07 - 137.61
Volume233,840
Avg. volume681,838
Market cap3.342B
Beta (5Y monthly)0.98
PE ratio (TTM)8.76
EPS (TTM)7.12
Earnings date29 Jul 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est92.17
  • Analysts Estimate Emergent Biosolutions (EBS) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Emergent Biosolutions (EBS) to Report a Decline in Earnings: What to Look Out for

    Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Motley Fool

    Can Emergent BioSolutions Recover From Its Recent Blunders?

    Emergent BioSolutions (NYSE: EBS) might disagree after its highly publicized COVID-19 vaccine manufacturing problems. In this Motley Fool Live video recorded on June 23, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer's question about whether or not Emergent BioSolutions can recover from its recent blunders. Brian Orelli: Yes, they can fix the issues that they had with the manufacturing and get better management in there to make sure that they're following all the FDA rules and good manufacturing practices.

  • Motley Fool

    Why Johnson & Johnson Is Trashing 60 Million Doses of Its COVID Vaccine

    Johnson & Johnson (NYSE: JNJ) hasn't become the major player in the COVID-19 vaccine market that many expected it to be, in large part because of manufacturing issues at a contractor's facility. Now, those issues have become even worse, and the Food and Drug Administration has told the healthcare giant that it must discard 60 million doses of its COVID-19 vaccine. In this Motley Fool Live video recorded on June 16, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why J&J is having to dump these vaccine doses.